Dosing

Taltz dosing for patients with moderate to severe plaque psoriasis1

The dosing regimen is the same for adult patients with moderate to severe plaque psoriasis and for adult patients with psoriatic arthritis* and coexistent moderate to severe plaque psoriasis

Dermatology dosing


Reminders1,5

  • If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time
  • Keep Taltz stored in the refrigerator between 2°C to 8°C (36°F to 46°F) and make sure it does not freeze. Do not use Taltz if it has been frozen
  • Remove Taltz from the refrigerator and let it warm to room temperature for 30 minutes before injecting
  • Protect Taltz from light until use. If needed, Taltz may be stored at room temperature up to 86°F (30°C) for up to 5 days in the original carton to protect from light until use. Once it has been stored at room temperature, it should not be returned to the refrigerator and should be discarded, if unused, within 5 days. Always handle carefully and never shake it. If you drop your device on a hard surface, do not use it. Use a new one for your injection
  • Keep Taltz and all medicines out of the reach of children
  • Read the Instructions for Use and Medication Guide before using Taltz

For detailed administration instructions, please have patients read the Instructions for Use included with the device.


SELECT IMPORTANT ADMINISTRATION INFORMATION

Patients may self-inject after training in subcutaneous injection technique. Instruct patients to inject the full amount and not to inject where the skin is tender, bruised, red, thick, or affected by psoriasis.


SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Taltz dosing for patients with psoriatic arthritis1

Rheumatology dosing

For patients with psoriatic arthritis and coexistent moderate to severe plaque psoriasis, follow the plaque psoriasis dosing.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time.

For detailed administration instructions, please have patients read the Instructions for Use included with the device.


SELECT IMPORTANT ADMINISTRATION INFORMATION

Patients may self-inject after training in subcutaneous injection technique. Instruct patients to inject the full amount and not to inject where the skin is tender, bruised, red, thick, or affected by psoriasis.


SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Devices



Taltz has 2 device options, offering you the flexibility to choose the one that best suits your patients1,6

Devices designed with patients in mind

Dosing devices

At first use, over 94% of patients with moderate to severe plaque psoriasis agreed the Taltz autoinjector was “easy to use” and were confident in their ability to use it.

Please see Instructions for Use included with the device.

Device study trial design


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018. 2. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013:133:17-26. 3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2013;141:133-142. 4. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178:1003-1005. 5. Taltz [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2018. 6. Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361-369.

Indications and Important Safety Information
Indications

Taltz is indicated for your adult patients with active psoriatic arthritis (PsA).

Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 01DEC2017